IsoRay, Inc. (ISR) Short Interest Down 2.9% in January

Share on StockTwits

IsoRay, Inc. (NYSEAMERICAN:ISR) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,065,703 shares, a decline of 2.9% from the January 15th total of 1,097,591 shares. Approximately 1.6% of the company’s shares are sold short. Based on an average trading volume of 349,208 shares, the days-to-cover ratio is presently 3.1 days.

ISR opened at $0.42 on Thursday. IsoRay has a 52-week low of $0.27 and a 52-week high of $1.22.

IsoRay (NYSEAMERICAN:ISR) last issued its earnings results on Tuesday, February 12th. The healthcare company reported ($0.02) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.02). The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.76 million.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Highland Private Wealth Management bought a new stake in IsoRay during the 4th quarter valued at $39,000. Vanguard Group Inc raised its position in IsoRay by 24.7% during the 3rd quarter. Vanguard Group Inc now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after purchasing an additional 367,324 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in IsoRay by 24.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after purchasing an additional 367,324 shares in the last quarter.

A number of equities analysts recently issued reports on ISR shares. Zacks Investment Research upgraded IsoRay from a “sell” rating to a “hold” rating in a report on Friday, November 9th. HC Wainwright restated a “buy” rating and set a $0.70 price objective on shares of IsoRay in a report on Monday, January 28th. Finally, Maxim Group cut IsoRay from a “buy” rating to a “hold” rating in a report on Friday, November 9th.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Macon Daily and is owned by of Macon Daily. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://macondaily.com/2019/02/14/isoray-inc-isr-short-interest-down-2-9-in-january.html.

IsoRay Company Profile

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Recommended Story: Do You Need a Fiduciary?

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply